Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study

This TOURMALINE-MM4 secondary analysis was performed to determine if the progression-free survival (PFS) benefit observed in newly-diagnosed multiple myeloma (NDMM) patients with maintenance ixazomib versus placebo was driven by a particular subgroup of patients. PFS benefit with ixazomib versus placebo was seen across all age and frailty status subgroups. Ixazomib prolonged PFS across the heterogeneous population of NDMM patients.

Source: Clinical Lymphoma, Myeloma and Leukemia - March 28, 2023 Category: Hematology Authors: Sara Bringhen, Lud ěk Pour, Reuben Benjamin, Sebastian Grosicki, Chang-Ki Min, Danielle Leao C． de Farias, Alexander Vorog, Richard J. Labotka, Bingxia Wang, Dasha Cherepanov, Lauren E. Cain, Sudhakar Manne, S. Vincent Rajkumar, Meletios A. Dimopoulos Source Type: research